All News

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

Ron Lanton III, Esq., discusses the Prescription Drug Price Relief Act of 2019 at the National Association of Specialty Pharmacists Annual Meeting at Washington, DC.

Top news of the day from across the health care landscape.

The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.

Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.

Top news of the day from across the health care landscape.

The FDA has awarded a cooperative agreement grant to the National Association of Boards of Pharmacy to develop a 3-year pilot project for a data-sharing system to improve oversight of compounding pharmacies.

Top news of the day from across the health care landscape.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

Just as vaccinations get under way in full force, a few indicators raise the question about whether the vaccine really is as well matched as was anticipated.

The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.

The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.

Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.

Top news of the day from across the health care landscape.

The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.

The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Findings published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) suggest that THC products are playing a role in the recent outbreak of lung injuries associated with e-cigarette and vape use.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Top news of the day from across the health care landscape.

Two lawsuits against the FDA have been resolved in a conclusion favorable to Endo International, which argued that vasporessin should be excluded from the agency’s compounding list.

Niraparib (Zejula) found to prolong time without symptoms or toxicity in patients with ovarian cancer.

Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.